Industry News
Pharmaceutical Industry News
ACG, a supplier for solid dose…
ACG, a supplier for solid dose drug manufacturers, is pumping $200 million into what will be the India-based company’s first empty-capsule production facility in the U.S.
As Big Pharmas increasingly roll…
As Big Pharmas increasingly roll out platforms for direct-to-consumer drug sales, most offering steep discounts on popular medications, many patients are open to using the new services, a recent survey found.
Merck has just registered the 15th…
Merck has just registered the 15th global phase 3 trial for its TROP2 antibody-drug conjugate, sac-TMT, just as its Chinese partner Kelun-Biotech reported two sets of strong phase 3 results in patients with lung cancer
Though spending on pharmaceutical…
Though spending on pharmaceutical TV ads picked up last month following a summer slump, the third quarter’s overall total still paled in comparison to the preceding periods this year.
Early Monday, Roche announced that…
Early Monday, Roche announced that the FDA cleared its 12-year-old oncology drug Gazyva to treat adults with active lupus nephritis who are taking standard therapy. The move into lupus nephritis comes late into the life
The investment is part of the New…
The investment is part of the New Jersey company’s plan to spend more than $70 billion on manufacturing, R&D and capital projects in the U.S. starting this year.
Theravance Biopharma is stepping…
Theravance Biopharma is stepping up efforts to educate physicians about neurogenic orthostatic hypotension associated with multiple system atrophy, launching its “Power in the Periphery” campaign in the run-up to publication of phase 3 data in
Novartis has shared detailed data…
Novartis has shared detailed data showing its radioligand therapy Pluvicto could slow the progression of certain hormone-sensitive prostate cancers ahead of a planned application with the FDA.
After upstaging Keytruda as…
After upstaging Keytruda as monotherapy for the treatment of first-line non-small cell lung cancer in China, Akeso and Summit Therapeutics’ ivonescimab has shown it could delay tumor progression versus another PD-1 inhibitor as part of
More than two years after a…
More than two years after a positive topline readout, AstraZeneca has to face the reality that a lack of an overall survival showing for its combo could prohibit a broader FDA approval in ovarian cancer.
Merck offered a closer look at…
Merck offered a closer look at Keytruda's overall survival benefits in a PD-L1-positive subgroup and its broader progression-free survival win at ESMO 2025.
The FDA has endorsed Amgen and…
The FDA has endorsed Amgen and AstraZeneca’s Tezspire as an add-on maintenance treatment for patients age 12 and older with chronic rhinosinusitis with nasal polyps. It is the second indication for Tezspire, which was originally
Fertility drugmaker EMD Serono,…
Fertility drugmaker EMD Serono, the U.S. arm of Merck KGaA, will offer its in vitro fertilization (IVF) treatments at a sharp discount on the government's DTC platform TrumpRx.
Trump Announces Proposals to Make I.V.F. More Affordable
The president unveiled several policy proposals on Thursday aimed at reducing the costs of in vitro fertilization. They included a deal with a pharmaceutical company to lower drug costs, and guidance encouraging employers to offer
In the first opportunity for…
In the first opportunity for industry watchers to compare the two approved TROP2 antibody-drug conjugates side by side in separate global phase 3 trials in the same disease setting, it’s AstraZeneca and Daiichi Sankyo’s Datroway
Results presented by AstraZeneca…
Results presented by AstraZeneca from its phase 3 trial of Imfinzi in patients with high-risk, non-muscle invasive bladder cancer (NMIBC) suggest that the PD-L1 inhibitor measures up to Pfizer’s PD-1 candidate sasanlimab.
Dianthus and Boehringer Ingelheim…
Dianthus and Boehringer Ingelheim headlined the latest round of licensing deals featuring China biotechs. Fierce's deep dive into the dispute between Novo Nordisk and KBP Biosciences wrapped up with Chapter 3. Takeda inked its second
With the launch of its first…
With the launch of its first direct-to-patient program, Genentech is joining the wave of drugmakers setting up direct-to-consumer sales of popular products at steep discounts for cash-paying patients.
The standing ovation for Keytruda…
The standing ovation for Keytruda and Padcev in metastatic bladder cancer at ESMO 2023 still echoes, and, now, the pair from Merck & Co., Pfizer and Astellas has pulled off similarly showstopping results in certain
A Keytruda-based regimen has shown…
A Keytruda-based regimen has shown a statistically significant overall survival benefit in all comers with platinum-resistant recurrent ovarian cancer regardless of their PD-L1 expression levels.